Literature DB >> 23420103

Bile Acid Receptors and Liver Cancer.

Xichun Wang1, Xianghui Fu, Carl Van Ness, Zhipeng Meng, Xiaoxiao Ma, Wendong Huang.   

Abstract

Liver cancer, particularly hepatocellular carcinoma (HCC), is the third leading cause of cancer death in the world. Bile acids (BAs) are liver-produced amphipathic molecules that are required to facilitate the absorption of cholesterol, fat-soluble vitamins, and lipids in the intestine. However, BAs are also known to act as potential carcinogens and deregulation of BA homeostasis has been linked to HCC formation. Two key BA receptors, farnesoid X receptor (FXR) and G protein-coupled bile acid receptor 1 (TGR5), were recently identified, which provides great insights into BAs' normal physiological functions as well as their carcinogenic effects. In this review, we focus on the potential links among BAs, two BA receptors, and HCC. FXR and TGR5 not only play key roles in regulating BA homeostasis but also are essential in suppressing BAs' carcinogenic effects on liver cancer.

Entities:  

Keywords:  Bile acids; FXR; Inflammation; Liver cancer; Metabolism; TGR5

Year:  2012        PMID: 23420103      PMCID: PMC3571718          DOI: 10.1007/s40139-012-0003-6

Source DB:  PubMed          Journal:  Curr Pathobiol Rep        ISSN: 2167-485X


  74 in total

1.  Endogenous bile acids as carcinogens.

Authors:  Peter L M Jansen
Journal:  J Hepatol       Date:  2007-06-14       Impact factor: 25.083

Review 2.  Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms.

Authors:  Danielle A A Hollman; Alexandra Milona; Karel J van Erpecum; Saskia W C van Mil
Journal:  Biochim Biophys Acta       Date:  2012-07-20

3.  Activation of farnesoid X receptor increases the expression of cytokine inducible SH2-containing protein in HepG2 cells.

Authors:  Zhizhen Xu; Gang Huang; Wei Gong; Yuanyin Zhao; Peng Zhou; Yijun Zeng; Fengtian He
Journal:  J Interferon Cytokine Res       Date:  2012-07-20       Impact factor: 2.607

Review 4.  Perspective: TGR5 (Gpbar-1) in liver physiology and disease.

Authors:  Verena Keitel; Dieter Häussinger
Journal:  Clin Res Hepatol Gastroenterol       Date:  2012-04-18       Impact factor: 2.947

5.  Bile acid-induced elevated oxidative stress in the absence of farnesoid X receptor.

Authors:  Masahiro Nomoto; Masaaki Miyata; Shanai Yin; Yasushi Kurata; Miki Shimada; Kouichi Yoshinari; Frank J Gonzalez; Kokichi Suzuki; Shigeki Shibasaki; Tohru Kurosawa; Yasushi Yamazoe
Journal:  Biol Pharm Bull       Date:  2009-02       Impact factor: 2.233

6.  Significance and mechanism of CYP7a1 gene regulation during the acute phase of liver regeneration.

Authors:  Lisheng Zhang; Xiongfei Huang; Zhipeng Meng; Bingning Dong; Steven Shiah; David D Moore; Wendong Huang
Journal:  Mol Endocrinol       Date:  2008-12-04

7.  Critical role of farnesoid X receptor for hepatocellular carcinoma cell proliferation.

Authors:  Tomofumi Fujino; Airi Takeuchi; Akiko Maruko-Ohtake; Yosuke Ohtake; Junichi Satoh; Tomonori Kobayashi; Toshiaki Tanaka; Haruka Ito; Ryosuke Sakamaki; Ryo Kashimura; Ken Ando; Tomoko Nishimaki-Mogami; Yasuhito Ohkubo; Naomi Kitamura; Ryuichiro Sato; Kiyomi Kikugawa; Makio Hayakawa
Journal:  J Biochem       Date:  2012-09-10       Impact factor: 3.387

8.  Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response.

Authors:  Yan-Dong Wang; Wei-Dong Chen; Meihua Wang; Donna Yu; Barry M Forman; Wendong Huang
Journal:  Hepatology       Date:  2008-11       Impact factor: 17.425

9.  Identification of a nuclear receptor that is activated by farnesol metabolites.

Authors:  B M Forman; E Goode; J Chen; A E Oro; D J Bradley; T Perlmann; D J Noonan; L T Burka; T McMorris; W W Lamph; R M Evans; C Weinberger
Journal:  Cell       Date:  1995-06-02       Impact factor: 41.582

10.  Hepatocellular carcinoma: natural history, current management, and emerging tools.

Authors:  Christopher L Tinkle; Daphne Haas-Kogan
Journal:  Biologics       Date:  2012-07-17
View more
  35 in total

Review 1.  Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD.

Authors:  Helen L Reeves; Marco Y W Zaki; Christopher P Day
Journal:  Dig Dis Sci       Date:  2016-02-26       Impact factor: 3.199

2.  Cytoplasmic tyrosine phosphatase Shp2 coordinates hepatic regulation of bile acid and FGF15/19 signaling to repress bile acid synthesis.

Authors:  Shuangwei Li; Diane D F Hsu; Bing Li; Xiaolin Luo; Nazilla Alderson; Liping Qiao; Lina Ma; Helen H Zhu; Zhao He; Kelly Suino-Powell; Kaihong Ji; Jiefu Li; Jianhua Shao; H Eric Xu; Tiangang Li; Gen-Sheng Feng
Journal:  Cell Metab       Date:  2014-06-26       Impact factor: 27.287

Review 3.  Bridging cell surface receptor with nuclear receptors in control of bile acid homeostasis.

Authors:  Shuangwei Li; Andrew Ni; Gen-sheng Feng
Journal:  Acta Pharmacol Sin       Date:  2014-12-15       Impact factor: 6.150

4.  Mice with hepatocyte-specific FXR deficiency are resistant to spontaneous but susceptible to cholic acid-induced hepatocarcinogenesis.

Authors:  Bo Kong; Yan Zhu; Guodong Li; Jessica A Williams; Kyle Buckley; Ossama Tawfik; James P Luyendyk; Grace L Guo
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-01-07       Impact factor: 4.052

Review 5.  Bile acid signaling and liver regeneration.

Authors:  Mingjie Fan; Xichun Wang; Ganyu Xu; Qingfeng Yan; Wendong Huang
Journal:  Biochim Biophys Acta       Date:  2014-05-27

Review 6.  The Hippo pathway in intestinal regeneration and disease.

Authors:  Audrey W Hong; Zhipeng Meng; Kun-Liang Guan
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-05-05       Impact factor: 46.802

7.  Circadian Misalignment and Hepatocellular Carcinoma Incidence in the United States.

Authors:  Trang VoPham; Matthew D Weaver; Céline Vetter; Jaime E Hart; Rulla M Tamimi; Francine Laden; Kimberly A Bertrand
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-04-10       Impact factor: 4.254

8.  Suppression of autophagic flux by bile acids in hepatocytes.

Authors:  Sharon Manley; Hong-Min Ni; Bo Kong; Udayan Apte; Grace Guo; Wen-Xing Ding
Journal:  Toxicol Sci       Date:  2013-11-04       Impact factor: 4.849

Review 9.  Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer.

Authors:  Abigale Lade; Luke A Noon; Scott L Friedman
Journal:  Curr Opin Oncol       Date:  2014-01       Impact factor: 3.645

Review 10.  From NASH to HCC: current concepts and future challenges.

Authors:  Quentin M Anstee; Helen L Reeves; Elena Kotsiliti; Olivier Govaere; Mathias Heikenwalder
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.